Watson buys rights to HRT (hormone replacement therapy) product:
This article was originally published in Clinica
Executive Summary
TheraTech, a wholly owned subsidiary of Watson Pharmaceuticals, has acquired marketing and distribution rights to the Alora oestradiol transdermal system from Procter & Gamble, which held exclusive rights since the product's US launch in 1997. Alora will now be marketed through Corona, California-based Watson's Women's Health division. TheraTech also bought back the rights to a development-stage oestradiol and progestin combination patch, while P&G retains global marketing and development rights to a range of female transdermal testosterone products.